When Cancer Strikes Twice: Understanding Renal Cell Carcinoma After Neuroblastoma
"A rare case study sheds light on the link between childhood neuroblastoma treatment and the development of renal cell carcinoma later in life, urging increased awareness and monitoring."
The diagnosis of renal cell carcinoma (RCC) in individuals who have previously battled neuroblastoma is an infrequent occurrence, demanding closer attention and research. A recent case involving a 26-year-old woman with a history of neuroblastoma prompted an investigation into the potential connections between these two distinct cancers.
This case study aims to determine whether a genetic predisposition or the treatments received for neuroblastoma might contribute to the later development of RCC. While a definitive explanation remains elusive, both genetic factors and prior treatments likely play a role in increasing the risk.
Given the limited number of documented cases and the scarcity of research into the genetic underpinnings of this particular type of RCC, it is crucial to document individual cases to broaden our understanding of this rare phenomenon.
Tracking RCC Burden
The National Cancer Institute's SEER Cancer Statistics tools provide cancer-site statistics by sex, race, calendar year, and age, with stage and histology available for selected cancers. NCCR*Explorer extends this framework to incidence and survival statistics for cancers affecting children, adolescents, and young adults ages 0-39. Kidney cancer includes renal cell carcinoma, which forms in the lining of kidney tubules, as well as renal pelvis carcinoma.
Diagnosis and Treatment Constraints
The ESMO Clinical Practice Guideline for renal cell carcinoma covers imaging, diagnosis, staging, risk assessment, treatment, and follow-up for localized and advanced or metastatic disease. Histopathological confirmation can come from a core biopsy of the renal tumor or metastatic site, or from examination of a nephrectomy specimen; histopathology also establishes the underlying subtype, including clear-cell or variant histology. Adult renal neuroblastoma remains rare, and a 2023 case report describes treatment with nephrectomy and adjuvant chemotherapy while noting that specific guidelines are limited by the condition's low incidence.
An Unsettled Disease Category
The concept of oncocytoid renal cell carcinoma in patients who survived neuroblastoma has been controversial since its original description in 1999. The controversy partly reflects reports of similar oncocytoid renal cell carcinomas associated with other pediatric conditions. A 26-year-old woman reported in JAMA had neuroblastoma during infancy, an extraadrenal pheochromocytoma at age 16, hepatic recurrences over the next ten years, and multifocal renal cell carcinoma.
Unpacking the Case: From Neuroblastoma to RCC
A 26-year-old woman, previously treated for neuroblastoma in childhood, presented with hematuria, leading to the discovery of two renal masses. Subsequent biopsies confirmed renal cell carcinoma (RCC), highlighting the need to investigate the potential link between these conditions.
- Neuroblastoma Diagnosis: Diagnosed at 18 months old, with tumors affecting the kidneys, tibia, and facial bones.
- Chemotherapy: Treated with melphalan for 22 weeks.
- Radiation Therapy: Received 2 Gy in 20 fractions following a laparotomy that revealed residual disease.
- Other Neoplasms: Developed multiple solid masses in adulthood, including leiomyomas, intra-abdominal fibromatosis, and colonic/rectal polyps.
- Liver Lesion: A stable lesion in the left lobe of the liver, suggestive of adenoma or focal nodular hyperplasia.
Secondary Renal Neoplasia Research
A review of secondary renal neoplasia following chemotherapy or radiation in pediatric patients reports 46 cases of neuroblastoma associated with renal neoplasia, including cases in the study's current series. Pediatric Xp11 translocation-associated renal cell carcinoma is described as a relatively common secondary malignancy in neuroblastoma patients. The cited work by Argani and colleagues found that 15% of patients with chromosomal translocations, including ASPSCR1-TFE3, had previously received cyclophosphamide, etoposide, or doxorubicin.
Evidence Remains Sparse
The literature emphasizes that RCC associated with neuroblastoma is a rare entity with limited evidence. One report states that only 23 cases had been reported when it described RCC in a 26-year-old patient with a previous neuroblastoma diagnosis. Another source notes that few cases and few genetic investigations of this RCC subtype make it important to continue adding individual cases to the literature. Imaging alone may not reliably distinguish renal neuroblastoma from RCC, although biopsy, urinary catecholamine levels, and metaiodobenzylguanidine scanning may assist presurgical diagnosis.
The Takeaway: Why Awareness is Key
Renal cell carcinoma following neuroblastoma treatment represents a distinct and rare subtype of RCC. The underlying reasons for this increased susceptibility in neuroblastoma survivors remain unclear but likely involve a combination of genetic predisposition and the effects of previous chemotherapy and radiation.
A Distinct RCC Association
An external expert opinion concluded that the lesion in the reported case fell within the spectrum of lesions known as RCC associated with neuroblastoma. The patient's right-sided partial nephrectomy showed papillary RCC without obvious unusual histologic features. The patient had been diagnosed with neuroblastoma at 18 months of age.
Evolving Treatment Strategies
Improved understanding of RCC biology has led to targeted agents and a paradigm shift in the management of metastatic RCC. A 2025 review describes advances in renal cancer diagnosis and treatment, including updated histological classification and imaging approaches using magnetic resonance imaging and computed tomography. A 2026 market analysis reports that combination regimens, guideline changes, and new second-line options are shaping the outlook for advanced RCC therapeutics through 2036.
A Long-Term Survivor Concern
Renal cell carcinoma associated with neuroblastoma is defined as RCC that develops in patients who are long-term survivors of childhood neuroblastoma. This framing places the condition within the broader challenge of recognizing a later renal malignancy after an earlier childhood cancer. Its definition specifically links the renal cancer to survivorship after childhood neuroblastoma.
One Patient's Second Cancer
A case report describes RCC arising in a 26-year-old patient with a history of neuroblastoma. The case illustrates the clinical reality of a second renal cancer occurring after childhood cancer, rather than presenting RCC as an isolated diagnosis. The report contributes a patient-level example to the literature on RCC after neuroblastoma.
Given the limited research and the small number of documented cases, continued reporting of individual cases is essential to improve our understanding of this phenomenon. Each new case contributes valuable data that can help researchers unravel the complex interplay of factors involved.
The development of multiple neoplastic lesions in this particular patient underscores the importance of long-term monitoring and awareness among clinicians caring for individuals with a history of childhood malignancies. Vigilance and early detection are critical for managing the increased risk of secondary cancers, particularly RCC, in adulthood.